Attorney Docket No.: 49673 (72024)

U.S.S.N.: 09/537,859 Filed: March 28, 2002

Amendment and Response to Final Office Action

Page 2 of 10

month, up to, and including, July 26, along with the necessary fee. A Notice of Appeal is filed herewith, along with the necessary fee. Please charge any additional fees required in connection with the papers transmitted herewith to Deposit Account No. 04-1105.

AMENDMENT

In the Specification

At page 6, please delete line 30, and insert therefore:

--Figure 1: shows the amino acid sequence of MCP-2 (SEQ ID NO. 1) and of its known variant (SEQ ID NO. 5). Signal---

Amendment Directing Entry Of Sequence Listing

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (3 pages) and number the pages as appropriate.

In the Claims

Please cancel claims 13-23.

Please add claims 24-30.

- 24. (New) An isolated amino-terminally truncated MCP-2 comprising residues 2-76 of an MCP-2 polypeptide according to SEQ ID NO: 2, wherein the truncated MCP-2 polypeptide lacks NH₂-terminal amino acid residue 1 and has chemokine antagonistic activity.
- 25. (New) An isolated amino-terminally truncated MCP-2 comprising residues 3-76 of an